KR20160141727A - Cd19-항체 약물 컨쥬게이트의 최적의 주입 - Google Patents

Cd19-항체 약물 컨쥬게이트의 최적의 주입 Download PDF

Info

Publication number
KR20160141727A
KR20160141727A KR1020167027123A KR20167027123A KR20160141727A KR 20160141727 A KR20160141727 A KR 20160141727A KR 1020167027123 A KR1020167027123 A KR 1020167027123A KR 20167027123 A KR20167027123 A KR 20167027123A KR 20160141727 A KR20160141727 A KR 20160141727A
Authority
KR
South Korea
Prior art keywords
dose
cd19a
sgn
administered
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167027123A
Other languages
English (en)
Korean (ko)
Inventor
바이텡 자오
티나 알버트슨
태 한
Original Assignee
시애틀 지네틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시애틀 지네틱스, 인크. filed Critical 시애틀 지네틱스, 인크.
Publication of KR20160141727A publication Critical patent/KR20160141727A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A61K47/4863—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020167027123A 2014-04-08 2015-04-07 Cd19-항체 약물 컨쥬게이트의 최적의 주입 Withdrawn KR20160141727A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461976790P 2014-04-08 2014-04-08
US61/976,790 2014-04-08
PCT/US2015/024732 WO2015157297A1 (en) 2014-04-08 2015-04-07 Optimal dosing of a cd19-antibody drug conjugate

Publications (1)

Publication Number Publication Date
KR20160141727A true KR20160141727A (ko) 2016-12-09

Family

ID=54288332

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167027123A Withdrawn KR20160141727A (ko) 2014-04-08 2015-04-07 Cd19-항체 약물 컨쥬게이트의 최적의 주입

Country Status (12)

Country Link
US (1) US20170182178A1 (enExample)
EP (1) EP3129052B1 (enExample)
JP (1) JP2017512801A (enExample)
KR (1) KR20160141727A (enExample)
CN (1) CN106170300A (enExample)
AU (1) AU2015244004A1 (enExample)
CA (1) CA2941154A1 (enExample)
EA (1) EA201692016A1 (enExample)
IL (1) IL247526A0 (enExample)
MX (1) MX2016012258A (enExample)
SG (1) SG11201607133QA (enExample)
WO (1) WO2015157297A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190233522A1 (en) * 2016-07-08 2019-08-01 Genmab A/S New dosage regimens for antibody drug conjugates based on anti-axl antibodies
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
CN109069584A (zh) * 2017-06-29 2018-12-21 成都华创生物技术有限公司 一种trail类蛋白持续抑制肿瘤细胞生长的给药方法
WO2019119822A1 (en) * 2017-12-23 2019-06-27 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2605443T3 (es) * 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CN101903403B (zh) * 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
JP6055404B2 (ja) * 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
JP6121906B2 (ja) * 2010-10-22 2017-04-26 シアトル ジェネティクス，インコーポレーテッド アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴｍＴＯＲ経路インヒビターの間の相乗効果
DK2714738T3 (en) * 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS

Also Published As

Publication number Publication date
EP3129052B1 (en) 2020-06-03
JP2017512801A (ja) 2017-05-25
AU2015244004A1 (en) 2016-09-15
US20170182178A1 (en) 2017-06-29
EP3129052A1 (en) 2017-02-15
EP3129052A4 (en) 2017-11-15
CA2941154A1 (en) 2015-10-15
MX2016012258A (es) 2017-01-06
EA201692016A1 (ru) 2017-01-30
IL247526A0 (en) 2016-11-30
WO2015157297A1 (en) 2015-10-15
SG11201607133QA (en) 2016-09-29
CN106170300A (zh) 2016-11-30

Similar Documents

Publication Publication Date Title
Cura et al. Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA2, NSC-624244) in patients with advanced cancer
Oldroyd et al. Interferon-γ inhibits experimental renal fibrosis
Selby et al. Tumour necrosis factor in man: clinical and biological observations
Den Broeder et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.
CN112546217B (zh) 用于治疗肿瘤的抗b7-h1抗体
US12144818B2 (en) Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimens
US20060171946A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
JP2019142961A (ja) Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用
Freytes et al. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation
JP4857259B2 (ja) 癌細胞増殖を阻害するための抗α５β１抗体の使用
AU2008265974B2 (en) Use of TACI-Ig fusion protein such as atacicept for the manufacture of a medicament for treating Lupus Erythematosus
Aung et al. Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes
KR20180121571A (ko) Liv1-adc와 화학요법제를 사용한 병용 요법
RU2454245C2 (ru) Фармацевтические композиции, способные вызывать апоптоз опухолевых клеток, для диагностики и лечения в-клеточной хронической лимфоцитарной лейкемии
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
CN119548617B (zh) 重组xvii型人源化胶原蛋白的新用途
EP3129052B1 (en) Optimal dosing of a cd19-antibody drug conjugate
Lu et al. Folate receptor-targeted aminopterin therapy is highly effective and specific in experimental models of autoimmune uveitis and autoimmune encephalomyelitis
CN113613678A (zh) 使用抗cd30抗体药物缀合物疗法治疗外周t细胞淋巴瘤的方法
Yawalkar et al. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab
KR20070036035A (ko) 자가면역 및 염증성 질환의 치료 방법
Kang et al. Effectiveness of antibody-drug conjugate (ADC): Results of in vitro and in vivo studies
US20150218286A1 (en) Methods of Treating Pediatric Acute Lymphoblastic Leukemia with an Anti-CD22 Immunotoxin
AU2005325227B2 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
Kim Daclizumab treatment for multiple sclerosis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160929

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination